AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific drug delivery technology, offers improved medical benefits and a potential for significant commercial development.
AlphaRx and Gaia BioPharma Secure Phase I/II Manufacturer for GAI-122 and Unveil Their Clinical Development Strategy
HONG KONG — (MARKET WIRE) — 01/21/10 AlphaRx Inc. (OTCBB: ALRX) announced today that its licensee, Gaia BioPharma Limited, has signed an agreement with a contract manufacturing organization (CMO) to manufacture GAI-122 for use in the planned Phase I and II clinical trials of that product candidate. GAI-122 is being developed as I.V. administered formulation [...]
AlphaRX – Review January 2010
After trading as high as $0.19 late last July the stock traded down to $0.07 on Dec. 7. During the dying days of 2009 the stock has traded wildly in a $0.075 to $0.16 range and closed out the year at $0.12. As much as I would like to offer a definitive opinion on [...]
AlphaRx’s Newly Appointed President of China Operations Unveils Strategic Corporate Initiatives
HONG KONG — (MARKET WIRE) — 12/21/09
AlphaRx Inc.’s (OTCBB: ALRX) recently appointed President of China Operations, Ruby Hui, today announced new corporate initiatives and the company’s strategic growth plan for China.
“When I was appointed as the President of AlphaRx China Operations a week ago, I promised that I would play a major part in AlphaRx’s [...]
AlphaRx Signs Contract Manufacturing Agreement for ARX1088
Hong Kong – December 17, 2009 – AlphaRx Inc. (OTCBB: ALRX) announced today that it has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of Hepatitis in China and other emerging markets. Under the agreement, Venturepharm will be [...]
AlphaRx Appoints President for its China Operations
“The Company is poised to become a leading drug developer in the pharmaceutical market in China and I’m looking forward to playing a major part in AlphaRx’s future and driving this company to new heights …”
Hong Kong – December 14, 2009 – AlphaRx Inc. (OTCBB: ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology [...]
AlphaRx Establishes Corporate Headquarters in Hong Kong and R&D Facility in Shanghai
Markham, Canada (December 3, 2009) – AlphaRx Inc. (OTCBB: ALRX), today announced that it has selected locations in Hong Kong and Shanghai for its corporate headquarters and a new R&D facility respectively. This initiative will spearhead a major push into Greater China.
The R&D facility will be located in The State Biotech Pharmaceutical industrial base (Shanghai) [...]
AlphaRX Review
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific drug delivery technology, offers improved medical benefits and a potential for significant commercial product development. [This appears on the bottom of their press releases.]
As can be seen on the [...]
